Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 11/07/2025 | CALL | $89.00 | 4,711 | +4,066 | +630.39% |
| 11/07/2025 | CALL | $86.00 | 1,781 | +1,399 | +366.23% |
| 11/14/2025 | CALL | $85.00 | 1,754 | +1,035 | +143.95% |
| 01/15/2027 | PUT | $75.00 | 3,343 | +673 | +25.21% |
| 11/21/2025 | CALL | $88.00 | 1,171 | +647 | +123.47% |
| 01/16/2026 | CALL | $90.00 | 27,009 | +510 | +1.92% |
| 01/16/2026 | PUT | $80.00 | 6,534 | -40 | -0.61% |
| 12/19/2025 | PUT | $65.00 | 5,992 | -41 | -0.68% |
| 11/14/2025 | PUT | $83.00 | 114 | -44 | -27.85% |
| 11/21/2025 | CALL | $95.00 | 12,637 | -50 | -0.39% |
| 01/16/2026 | PUT | $75.00 | 10,426 | -96 | -0.91% |
| 01/16/2026 | CALL | $100.00 | 18,495 | -258 | -1.38% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.04% | 77.07M | 8.28B |
| Vanguard 500 Index Fund | 2.31% | 58.61M | 6.3B |
| Fidelity 500 Index Fund | 1.09% | 27.79M | 2.99B |
| SPDR S&P 500 ETF Trust | 1.08% | 27.45M | 2.95B |
| iShares Core S&P 500 ETF | 0.89% | 22.63M | 2.43B |
| Vanguard Index-Value Index Fund | 0.86% | 21.91M | 2.35B |
| Select Sector SPDR Fund-Health Care | 0.81% | 20.59M | 2.21B |
| Vanguard Specialized-Health Care Fund | 0.72% | 18.31M | 1.97B |
| Vanguard Institutional Index Fund-Institutional Index Fund | 0.70% | 17.77M | 1.91B |
| Schwab Strategic Tr-Schwab U.S. Dividend Equity ETF | 0.68% | 17.38M | 1.87B |
Companion Animal Health Market to Worth USD 61.74 Billion by 2034, Driven by Rising Pet Ownership and Humanization Trends
10/31 10:00 am
GlobeNewswire Inc.
Read moreAdagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
10/31 07:00 am
GlobeNewswire Inc.
Read moreKuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030
10/31 06:19 am
Benzinga
Read moreMerck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook
10/30 12:24 pm
Benzinga
Read moreCell-based Assays Market Size to Reach USD 35.34 Billion by 2032, Driven by Demand for Drug Discovery and Advanced Biotechnology Research – SNS Insider
10/30 04:59 am
GlobeNewswire Inc.
Read morePharmaceutical Market to Reach USD 3,033.21 Billion by 2034 Driven by Rising Geriatric Population
10/29 11:00 am
GlobeNewswire Inc.
Read moreMerck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer
10/28 01:40 pm
Benzinga
Read moreStep Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
10/28 08:00 am
GlobeNewswire Inc.
Read moreHealthcare M&A Activity Increases 7% in Q3:25
10/27 11:38 am
Benzinga
Read more3 Healthcare Stocks That Are Screaming Deals Right Now
10/26 04:23 pm
The Motley Fool
Read moreWhy Some Investors Are Taking Profits on JPMorgan After Its Big Rally
10/23 04:08 pm
The Motley Fool
Read morePrediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.
10/22 01:10 pm
The Motley Fool
Read moreHCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment
10/22 09:00 am
GlobeNewswire Inc.
Read moreFlare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
10/21 07:00 am
GlobeNewswire Inc.
Read moreSmall Cell Lung Cancer Market Research 2025-2035: Growth Driven by Advancements in Novel Therapies, Including Immunotherapies, Targeted Therapies, and Combination Treatments
10/21 04:41 am
GlobeNewswire Inc.
Read moreWhat's Going On With Summit Therapeutics Stock On Monday?
10/20 10:05 am
Benzinga
Read more2 Beaten-Down Stocks to Buy and Hold for the Next Decade
10/20 09:07 am
The Motley Fool
Read moreCell Encapsulation Market Analysis, Trends, Growth Drivers and Future Opportunities | Towards Healthcare Insight
10/20 09:00 am
GlobeNewswire Inc.
Read moreMerck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
10/16 10:33 am
Benzinga
Read moreIs Recursion Pharmaceuticals a Millionaire Maker?
10/16 09:31 am
The Motley Fool
Read moreWhy Moderna Might Be a One-Hit Wonder
10/15 04:08 pm
The Motley Fool
Read moreMerck's New HIV Treatment Works As Well As Top Drug In Late Trials
10/15 12:23 pm
Benzinga
Read moreAbsci Stock Offers High-Risk AI Biotech Exposure With 110% Upside Forecast
10/14 11:41 am
Investing.com
Read moreDrug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
10/13 06:10 am
The Motley Fool
Read moreThe Best Dividend ETF to Invest $1,000 in Right Now
10/12 01:05 pm
The Motley Fool
Read moreMolecule Therapeutics Market Size, Companies and Emerging Technologies Insight – Towards Healthcare
10/10 09:00 am
GlobeNewswire Inc.
Read moreMERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
10/08 02:59 pm
GlobeNewswire Inc.
Read moreMerck, Doctors Reject Proposal To Break Up Combined MMR Vaccine
10/07 02:02 pm
Benzinga
Read moreAcquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
10/06 04:05 pm
Benzinga
Read morePreclinical Advanced Cell Models Market Segmentations and Regional Focused Report (2025 – 2034)
10/06 09:00 am
GlobeNewswire Inc.
Read moreEvaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
10/03 09:00 am
GlobeNewswire Inc.
Read more6 Healthcare Stocks Positioned to Soar After Trump-Pfizer Deal
10/02 12:15 pm
Investing.com
Read moreShould You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
10/02 11:37 am
The Motley Fool
Read moreIncendia Therapeutics Presents Two Posters on its Lead Asset PRTH-101 in Thymic Cancers at the 15th International Thymic Malignancy Interest Group (ITMIG) Annual Meeting
10/02 09:00 am
GlobeNewswire Inc.
Read moreMultiple Modalities in the Oncology Market Size, Regional Growth and Trends
09/30 11:00 am
GlobeNewswire Inc.
Read moreMerck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients
09/30 09:47 am
Benzinga
Read more2 Beaten-Down Stocks to Buy and Hold for a Decade
09/30 07:30 am
The Motley Fool
Read moreNeuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
09/29 04:54 pm
GlobeNewswire Inc.
Read morePhosphoramidites Market Research and Forecast Report 2025-2035: Essential Role in DNA/RNA Synthesis Drives Growth in Gene Therapy, Molecular Diagnostics and Personalized Medicine
09/29 05:53 am
GlobeNewswire Inc.
Read moreRobert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough'
09/26 12:08 am
Benzinga
Read moreUnited Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO
09/24 02:15 pm
Benzinga
Read morePneumococcal Vaccine Market Opportunities and Strategies to 2034 - Pediatric Segment Holds the Major Opportunity in Market Expansion
09/24 12:48 pm
GlobeNewswire Inc.
Read moreFDA Clears Merck's One-Minute Cancer Shot
09/22 01:23 pm
Benzinga
Read moreAdvancing Cancer Research Brings New Hope for Patients Worldwide
09/17 08:30 am
Benzinga
Read moreHCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
09/16 08:00 am
GlobeNewswire Inc.
Read more2 Healthcare Dividend Stocks to Buy and Hold
09/14 07:15 am
The Motley Fool
Read moreSummit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
09/08 08:28 am
Benzinga
Read moreImmutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
09/08 08:00 am
GlobeNewswire Inc.
Read more